MedTrace Logo

Novel Desensitization Kidney Transplantation

NCT05345717 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-12-09

No results posted yet for this study

Summary

This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.

Conditions

  • Kidney Transplantation
  • End Stage Kidney Disease (ESRD)

Interventions

DRUG

Belatacept Injection

Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Piotr Witkowski, MD PhD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-09-12
Completion
2025-09-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345717 on ClinicalTrials.gov